Day One Biopharmaceuticals stock (US23933J1034): Servier takeover crowns Ojemda growth story

French pharma group Servier is taking Day One Biopharmaceuticals private in a $2.5 billion all?cash deal at $21.50 per share, a 68% premium that highlights the value of its pediatric brain cancer drug Ojemda and ongoing commercial ramp.

French drugmaker Servier is set to acquire rare oncology specialist Day One Biopharmaceuticals in an all?cash deal valuing the US company at about $2.5 billion, or $21.50 per share, representing a 68% premium to the prior close on March 5, 2026, according to Kavout as of 03/06/2026. The transaction gives shareholders immediate cash and caps a period of strong revenue growth from the pediatric brain cancer drug Ojemda.

Day One Biopharmaceuticals also reported rising product sales in its most recent quarterly filing. In the third quarter of 2025, total revenue reached $39.8 million, mainly driven by $38.5 million in product revenue, compared with $20.1 million in the prior?year quarter, according to a summary of the company’s Q3 2025 Form 10?Q filed with the US Securities and Exchange Commission and reported by StockTitan as of 11/07/2025.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Day One Biopharmaceuticals
• Sector/industry: Biotechnology, oncology
• Headquarters/country: Brisbane, California, United States
• Core markets: Pediatric and rare oncology, primarily US and Europe
• Key revenue drivers: Ojemda (tovorafenib) for pediatric low?grade glioma and related RAF?pathway tumors
• Home exchange/listing venue: Nasdaq (ticker: DAWN)
• Trading currency: US dollar (USD)

Day One Biopharmaceuticals: core business model

Day One Biopharmaceuticals focuses on developing and commercializing targeted cancer therapies for children and adults with tumors driven by specific genetic alterations. The company’s strategy centers on identifying signaling pathways with well?defined biology, designing selective inhibitors and then building clinical programs around genetically selected patient populations. This approach aims to deliver therapies with clearer benefit?risk profiles and potential for regulatory approvals in indications with high unmet medical need.

The company’s name reflects its stated goal of ensuring that children with cancer have access to the same innovative therapies as adults from the first day of treatment. Rather than retrofitting adult cancer drugs for pediatric use late in development, Day One Biopharmaceuticals has positioned itself to include children earlier in the clinical trial process. Its lead asset, Ojemda (tovorafenib), originated from this philosophy and was advanced through trials that enrolled both pediatric and certain adult patients with RAF?altered tumors.

Commercialization has become a central part of Day One’s business model since regulatory approval of Ojemda. The company has built a focused commercial infrastructure in the United States, targeting pediatric oncologists and specialized treatment centers. At the same time, it has pursued partnerships and regulatory pathways in Europe and other regions to expand access outside the US, allowing it to keep its internal organization relatively lean while still reaching broader markets.

Main revenue and product drivers for Day One Biopharmaceuticals

Ojemda is the primary revenue driver for Day One Biopharmaceuticals. The oral, brain?penetrant type II pan?RAF inhibitor is approved by the US Food and Drug Administration for the treatment of children with relapsed or refractory low?grade glioma harboring BRAF alterations, a rare but serious childhood brain tumor. Following its launch, product revenue has grown rapidly as physicians gain experience and testing for BRAF alterations becomes more widely adopted, according to the company’s 2025 quarterly filings summarized by StockTitan as of 11/07/2025.

The third quarter of 2025 illustrates this ramp. Day One reported total revenue of $39.8 million for the period ended September 30, 2025, with $38.5 million attributed to product sales, up from $20.1 million in the same quarter of 2024. The prior year’s quarter also included significant license revenue that boosted reported net income at that time, making the year?over?year comparison more complex. In Q3 2025, the company posted a net loss of $19.7 million, compared with net income of $37.0 million in Q3 2024, reflecting higher operating expenses as the commercial rollout progressed.

On a year?to?date basis for 2025, Day One generated $104.5 million in revenue, of which $102.6 million came from product sales, demonstrating that Ojemda had become the dominant contributor to the top line. Operating expenses for Q3 2025 totaled $64.0 million, including research and development costs of $31.4 million and selling, general and administrative expenses of $28.1 million. These figures show the dual priorities of funding clinical development while supporting a growing commercial presence, a common pattern among emerging biotech companies with their first approved product.

The company’s balance sheet at the end of the third quarter of 2025 also played an important role in supporting its strategy. Day One reported cash and cash equivalents of $43.3 million and short?term investments of $408.3 million, for total assets of $513.8 million and stockholders’ equity of $450.9 million as of September 30, 2025, according to the same SEC filing summary by StockTitan as of 11/07/2025. This cash position allowed continued investment in pipeline programs and international expansion efforts even as the company remained loss?making on a net income basis.

Beyond Ojemda, Day One has built a pipeline of RAF?pathway and other targeted agents aimed at expanding its addressable markets. While detailed program timelines and trial designs vary, the central idea is to leverage existing expertise in RAF signaling and pediatric oncology to pursue additional indications, including adult tumors with relevant genetic mutations. For acquirers such as Servier, this portfolio offers potential long?term growth options on top of the near?term cash flows from Ojemda.

Servier’s $2.5 billion acquisition: terms and strategic rationale

The acquisition by Servier marks a significant milestone for Day One shareholders and patients. Under the deal, Servier agreed to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.5 billion. The price represents a 68% premium over Day One’s closing share price on March 5, 2026, and an 86% premium over its one?month volume?weighted average price, according to Kavout as of 03/06/2026.

The transaction structure is all?cash, providing immediate liquidity to existing investors and effectively taking Day One private once the deal closes. According to coverage of the definitive agreement, the takeover is expected to complete in the second quarter of 2026, subject to customary closing conditions such as antitrust clearance in the United States and the tender of a majority of outstanding shares, as described by Kavout as of 03/06/2026. For Day One, the deal offers access to a larger global infrastructure, while Servier gains a foothold in US?based rare oncology with an already approved product.

Servier’s strategic rationale centers on strengthening its position in high?growth oncology niches, particularly rare cancers where targeted therapies can command premium pricing and face less direct competition. Day One’s portfolio aligns with Servier’s stated ambition to become a leading player in rare oncology by 2030, with Ojemda serving as the centerpiece. The French company brings an established commercial footprint in Europe and other regions, potentially accelerating the geographic expansion of Ojemda and later pipeline assets, as highlighted in the analysis by Kavout as of 03/06/2026.

The purchase price underscores Servier’s confidence in the long?term value of Ojemda and related programs. Paying a 68% premium over the undisturbed share price is a strong signal in the current biotech dealmaking environment, where many small and mid?cap companies have faced pressure on valuations. For Day One shareholders, the premium crystallizes expectations about future growth into a near?term cash payout, while for Servier the deal represents a significant capital allocation bet on pediatric brain cancer and RAF?pathway biology.

Regulatory milestones and international expansion for Ojemda

Regulatory progress has been an important backdrop to the takeover announcement. Ojemda received US FDA approval in 2024 for the treatment of relapsed or refractory pediatric low?grade glioma with BRAF alterations, establishing Day One as a commercial?stage company in the United States. Subsequent clinical data and real?world experience have supported adoption in specialized centers, helping to drive the revenue growth seen in 2025, as described in SEC filings summarized by StockTitan as of 11/07/2025.

In Europe, Ojemda reached a key milestone when it received a conditional marketing authorization recommendation from the European Medicines Agency’s relevant committee in February 2026. The recommendation covers use in children with relapsed or refractory BRAF?altered low?grade glioma and provides a pathway to broader European Union approval, according to an overview of the deal context by Kavout as of 03/06/2026. For Servier, which has deep roots in Europe, integrating Ojemda into its regional oncology portfolio could unlock additional patient access and revenue streams.

Beyond the US and EU, Day One and its new parent will likely evaluate opportunities in other regions where pediatric oncology infrastructure and diagnostic capabilities support targeted therapies. Markets in Asia?Pacific and Latin America present both opportunities and challenges, including heterogeneous reimbursement systems and varying levels of access to molecular testing. With Servier’s broader global footprint, Day One’s products may benefit from established commercial networks and relationships with regulators and payers, which can be particularly valuable for small companies transitioning from single?market to multi?region operations.

The conditional nature of some approvals, especially in Europe, typically entails post?authorization study requirements. These commitments can include additional trials, long?term safety follow?up and real?world evidence collection to confirm clinical benefit in broader populations over time. Meeting these obligations demands both financial resources and operational expertise, which Servier’s larger organization may be better positioned to provide compared with a standalone biotech.

Why Day One Biopharmaceuticals matters for US investors

For US investors, Day One Biopharmaceuticals has been part of a broader story about how innovative cancer therapies transition from early?stage biotech portfolios into the hands of larger pharmaceutical companies. Listed on Nasdaq under the ticker DAWN, the company provided exposure to pediatric and rare oncology, a segment that historically has been underrepresented yet offers potentially durable demand due to the lack of alternative treatments. The Servier deal illustrates how strategic buyers may be willing to pay substantial premiums for assets that combine regulatory validation, early commercial traction and a specialized focus.

Even though the acquisition effectively caps the upside for public shareholders at the agreed cash price, it also reduces uncertainty around the pace of adoption, reimbursement dynamics and long?term competitive threats. In the US market, where volatility in small?cap biotech stocks can be high, an all?cash offer at a significant premium can be seen as crystallizing value that might otherwise have taken years to realize through organic growth alone. The transaction also highlights the importance of M&A as a potential exit route for investors in development?stage and early commercial biotechs.

More broadly, the Day One?Servier combination feeds into sector?wide themes that matter for US portfolios. Large pharmaceutical groups continue to look for targeted oncology assets to offset patent expirations and to strengthen growth profiles. Successful takeovers at robust premiums can influence sentiment and valuations across peer companies with similar profiles, such as those holding first?in?class or best?in?class therapies for genetically defined patient subgroups. For diversified investors, transactions like this can also serve as a reminder of the binary outcomes often associated with biotech investing and the role that strategic buyers play in setting terminal values.

Conclusion

The planned acquisition of Day One Biopharmaceuticals by Servier at $21.50 per share in cash closes a notable chapter for a company that rapidly transitioned from development?stage biotech to commercial player in pediatric brain cancer. The premium valuation reflects confidence in Ojemda’s market potential and in the broader strategic value of a focused rare oncology platform. For US investors, the transaction underscores how regulatory approvals, early sales momentum and a specialized pipeline can translate into attractive takeout terms, while also illustrating the trade?off between ongoing exposure to execution risk and the certainty of a negotiated cash exit.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.